:::

學術成果

:::
搜尋
年至

月至


  • 關鍵字搜尋
  • 期刊論文
    學年度著作著作人
    101Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA.,2012,Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.,Lancet Oncol.,13,5,pp539-548 (SCI)楊志新
    101Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ, Lorence RM, Yang JC*.,2012,Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.,Lancet Oncol.,13,5,pp528-538 (SCI)楊志新
    101Su KY, Chen HY, Li KC, Kuo ML, Yang JC, Chan WK, Ho BC, Chang GC, Shih JY, Yu SL, Yang PC.,2012,Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non-Small-Cell Lung Cancer.,Journal of Clinical Oncology,30,2,pp433-440 (SCI)楊志新
    101Chung KP, Huang YT, Chang YL, Yu CJ, Yang CH, Chang YC, Shih JY, Yang PC.,2012,Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment.,Chest.,141,2,pp420-428 (SCI)楊志新
    101Wu SG, Kuo YW, Chang YL, Shih JY, Chen YH, Tsai MF, Yu CJ, Yang CH, Yang PC.,2012,EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.,J Thorac Oncol.,7,1,pp98-104 (SCI)楊志新
    1011. Wu, S.J., Kuo, Y.Y.*, Hou, H.A., Li, L.Y., Tseng, M.H., Huang, C.F., Lee, F.Y., Liu, M.C., Liu, C.W., Lin, C.T., Chen, C.Y., Chou, W.C., Yao, M., Huang, S.Y., Ko, B.S., Tang, J.L., Tsay, W., and Tien, H.F.*,2012,The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution.,Blood. ,120,pp3106-3111 (SCI)郭遠燁
    101Hou, H.A.#, Kuo, Y.Y.#, Liu, C.Y., Chou, W.C., Lee, M.C., Chen, C.Y., Lin, L.I., Tseng, M.H., Huang, C.F., Chiang, Y.C., Lee, F.Y., Liu, M.C., Liu, C.W., Tang, J.L., Yao, M., Huang, S.Y., Ko, B.S., Hsu, S.C., Wu, S.J., Tsay, W., Chen, Y.C., Tien, H.F.,2012,DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. ,Blood.,119,2,pp559-568 (SCI)郭遠燁
    101Huang MH, Lee JH, Chang YJ, Tsai HH, Lin YL, Lin MY, Yang JC*. ,2012,MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib.(accepted),Molecular Oncology (SCI)楊志新
    101Kuo YH, Lin ZZ, Yang YY, Shao YY, Shau WY, Kuo RN, Yang JC and Lai MS.,2012,Survival of patients with small cell lung cancer in Taiwan. ,Oncology,82,1,pp19-24 (SCI)楊志新
    101Velentgas P, Amato AA, Bohn RL, Chan KA, Cochrane T, Funch DP, Dashevsky I, Duddy AL, Gladowski P, Greenberg SA, Kramer JM, McMahill-Walraven C, Nakasato C, Spettell CM, Syat BL, Wahl PM, Walker AM, Zhang F, Brown JS, Platt R. ,2012,Risk of Guillain–Barré syndrome after meningococcal conjugate vaccination.,Pharmacoepidemiology and Drug Safety,21,12,pp1350-1358 (SCI)陳建煒